Pea M, Bonetti F, Martignoni G, Henske E P, Manfrin E, Colato C, Bernstein J
Istituto di Anatomia Patologica, Università di Verona, Italy.
Am J Surg Pathol. 1998 Feb;22(2):180-7. doi: 10.1097/00000478-199802000-00005.
Renal epithelial tumors (carcinoma and oncocytoma) have been reported with higher a frequency than expected in patients with the tuberous sclerosis complex. However, the recent identification of a monotypic, epithelioid variant of angiomyolipoma, closely simulating renal cell carcinoma, has cast doubt on the real frequency of carcinoma. Immunohistochemical analysis with a panel of antibodies, including melanogenesis marker HMB45, can discriminate between carcinoma and carcinoma-like angiomyolipoma. We studied five tumors previously reported as carcinoma and found that only one of them showed an immunohistochemical phenotype indicative of an epithelial tumor (Ker+, HMB45-). Three tumors exhibited a phenotype compatible with the monotypic epithelioid variant of angiomyolipoma (HMB45+, Ker-), and two of the three patients died of metastatic disease. The last patient had unusual clinical features, and the tumor was positive both for HMB45 and keratin. It is concluded that (1) renal cell carcinoma is less common in tuberous sclerosis complex than previously believed, (2) some cases called renal cell carcinoma probably represent a monotypic, epithelioid variant of angiomyolipoma, and (3) epithelioid angiomyolipoma is a potentially malignant tumor with invasion and metastases. These findings indicate that all reported renal carcinomas in tuberous sclerosis complex, therefore, must be reevaluated.
据报道,在结节性硬化症患者中,肾上皮肿瘤(癌和嗜酸细胞瘤)的发生频率高于预期。然而,最近发现一种单型、上皮样血管平滑肌脂肪瘤变体,与肾细胞癌极为相似,这使得人们对癌的实际发生频率产生了怀疑。使用包括黑色素生成标志物HMB45在内的一组抗体进行免疫组织化学分析,可区分癌和癌样血管平滑肌脂肪瘤。我们研究了5例先前报告为癌的肿瘤,发现其中只有1例显示出指示上皮肿瘤的免疫组织化学表型(角蛋白阳性、HMB45阴性)。3例肿瘤表现出与血管平滑肌脂肪瘤单型上皮样变体相符的表型(HMB45阳性、角蛋白阴性),这3例患者中有2例死于转移性疾病。最后1例患者具有不寻常的临床特征,其肿瘤的HMB45和角蛋白均呈阳性。得出的结论是:(1)结节性硬化症患者中的肾细胞癌比先前认为的更少见;(2)一些被称为肾细胞癌的病例可能代表血管平滑肌脂肪瘤的单型上皮样变体;(3)上皮样血管平滑肌脂肪瘤是一种具有侵袭和转移能力的潜在恶性肿瘤。这些发现表明,因此,所有报道的结节性硬化症患者中的肾癌都必须重新评估。